Aurobindo Pharma’s wholly owned subsidiary -- Apitoria Pharma has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Unit-VI at API manufacturing facility, situated at E-Bonangi Village, Parawada Mandal, Anakapalli District, Andhra Pradesh. The API manufacturing facility has been classified as Voluntary Action Indicated (VAI). The USFDA has concluded that this inspection is now closed.
Earlier, the inspection was conducted from August 24 to August 28, 2026, and concluded with three observations.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.